Börsipäev 19. september
Log in or create an account to leave a comment
-
Olgugi et S&P 500 indeksil õnnestus eelmisel nädalal parandada taset poole protsendi jagu, osutus liikumine paljude silmis tõenäoliselt pettumust valmistavaks, sest 9. septembri -2,5% kukkumise järel on vanadele tasemetele tagasijõudmine osutunud arvatust vaevalisemaks, mis võib viidata sellele, et ostjad vajavad kasvanud volatiilsuse juures julgemaks sekkumiseks madalamaid hinnatasemeid. Närvilisus on kasvanud Euroopaski, kus Stoxx 600 pidi nädala lõikes vastu võtma -2,2% kaotuse.
Mitu kuud rahulikus vees seilanud aktsiaturgusid raputab praegu üsna pikk nimekiri erinevatest teguritest, alates hooajalisest nõrkusest, lõpetades ettevõtete kahanevate kasumite, rahapoliitilise ebakindluse ning uuesti aeglustuma hakanud USA majandusega. Tarbija on jätkuvalt vedamas Ühendriikide majandust, kuid nagu möödunud nädalal avaldatud augustikuu jaemüük näitas, on tugevama teise kvartali järel kulutuste hoog raugenud, sundides analüüsimajasid korrigeerima oma majanduskasvu ootusi allapoole.
Atlanta FEDi mudeli kohaselt peaks USA SKP kasv ulatuma kolmandas kvartalis 3,0%ni võrreldes septembri alguses prognoositud 3,5%ga. Aasta lõpp toob taas pehmema näitaja, kui NY FEDi mudeli hinnangul peaks majanduskasv neljandas kvartalis aeglustuma 1,7% peale.
Paljud FOMC liikmed on viimase kuu jooksul argumenteerinud intressimäära tõstmise kasuks, sh ka Janet Yellen 26. augustil Jackson Hole’is esinedes. Üldiselt on aga välditud seisukoha võtmist, kas see võiks juhtuda just käesoleva nädala istungil ja kuna FOMC langetab otsuseid jooksvatele majandusnäitajatele tuginedes (mis on jäänud arvatust nõrgemaks), siis on turuosaliste silmis vähetõenäoline, et USA keskpank otsustab 21. septembril rahapoliitikat karmistada.
Keskpangad jäävad sel nädalal domineerima sentimenti finantsturgudel, sest lisaks FOMC-le tuleb kolmapäeval kokku ka Jaapani keskpank, mille nõukogus puudub ajakirjanduse kohaselt samuti selge üksmeel, kas majandust tuleks täiendavalt stimuleerida või mitte.
Tänased majandusuudised:
17.00 USA majade ehitajate kindlustunde indeks (september) -
Uute majade hinnatõus Hiinas on vaatamata suurlinnade karmimatele regulatsioonidele augustis uuesti kiirenenud, kergitades 70 linna keskmist YoY hinnakasvu 7,3%ni (juulis 6,13%)
-
Ghana central bank leave interest rate unchanged at 26%.
-
Gapping up
In reaction to strong earnings/guidance: TERP +1%, (releases prelim Q2 results with adj $152--160 mln and adj revs $198-206 mln)
M&A news:
ISLE +28.4% (to be acquired by Eldorado Resorts (ERI) for $23.00/share in cash or 1.638 shares of ERI stock)
BLOX +15.3% (confirms it will be acquired by Vista Equity Partners for $26.50 per share in cash)
TECD +7.1% (to acquire the Technology Solutions biz from Avnet (AVT))
HMY +2.7% (Harmony Gold acquires full ownership of the Hidden Valley mine from Newcrest Mining (NCMGY) in New Guinea)
Select EU financial related names showing strength: BCS +2.4%, HSBC +1.9%, SAN +1.6%, ING +1.4%, .
Select metals/mining stocks trading higher: BHP +2.8%, PAAS +2.1%, AU +2%, SLV +1.9%, FCX +1.8%, SLW +1.6%, GOLD +1.5%, ABX +1.2%, .
Select oil/gas related names showing strength: SDRL +2.8%, CHK +2.3%, MRO +2.2%, BP +2%, RDS.A +1.8%, TOT +1.4%, .
Other news:
NBY +21.6% (announces that data from a Phase 2b clinical study with Auriclosene Irrigating Solution demonstrated statistically significant and clinically meaningful results in the prevention of urinary catheter blockage and encrustation)
NVAX +8.5% (modestly rebounding following last week's declines)
CFRX +4.8% (promotes Cara Cassino, MD to Chief Medical Officer and Executive VP of Research and Development effective Oct 1)
GPRO +3.9% (ahead of new product launch event (including Karma drone))
CLCD +2.8% (reports its SAMURAI achieves secondary endpoints)
RDUS +2.3% (reports new positive results from the Phase 3 ACTIVE Trial of Abaloparatide published in JBMR)
Analyst comments:
AKS +4.4% (upgraded to Sector Weight from Underweight at KeyBanc)
X +2.8% (upgraded to Sector Weight from Underweight at KeyBanc)
GM +2.7% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
KBH +2.2% (upgraded to Buy from Neutral at Buckingham Research)
EPD +1.4% (upgraded to Outperform from Neutral at Credit Suisse)
RBS +1.2% (upgraded to Hold from Sell at Investec)
WFC +0.9% (upgraded to Outperform from Neutral at Robert W. Baird)
TRGP +0.9% (upgraded to Buy from Neutral at Goldman)
Gapping down
In reaction to disappointing earnings/guidance: N/A.
M&A news:
CYH -2.4% (confirms it is exploring a variety of options with financial sponsors, as well as other potential alternativesg)
Other news:
VICL -18.7% (Vical and Astellas (ALPMY) announce topline results from a randomized, double-blind, placebo-controlled Phase 2 study evaluating the safety and efficacy of cytomegalovirus)
CVRR -13.3% (still checking, stock moved aggressively higher in final minutes of trading on Friday; may be attributed to that)
ORMP -3% (still checking)
DEPO -0.9% (confirms it received request to call special meeting of shareholders)
TEVA -0.5% (announces Results from Exploratory 52-Week Phase 2 PRIDE-HD Study of Pridopidine in Huntington Disease)
Analyst comments:
OSUR -2.1% (downgraded to Neutral from Buy at BTIG Research)
CALD -1.5% (downgraded to Sell from Neutral at Dougherty & Company)
PYPL -1.1% (downgraded to Hold from Buy at Canaccord Genuity)
Briefing.com
